Heterobicyclic metalloprotease inhibitors

US7795245B2 · kind B2 · utility

Assignee

• Atlantos Pharmaceuticals Holding, Inc. · US

Inventors

• Christoph Steeneck · Dossenheim, DE
• Christian Gege · Ehingen (Donau), DE
• Frank Richter · Dossenheim, DE
• Heiko Kroth · Ecublens, CH
• Matthias Hochgürtel · Schriesheim, DE
• Michael Essors · Sonneberg, DE
• Joshua J. Van Veldhuizen · Seattle, US
• Bert Nolte · Aachen, DE
• Brian Gallagher · Merrimac, US
• Tim Feuerstein · Neckargemünd, DE
• Matthias Schneider · Dossenheim, DE
• Torsten Arndt · Bensheim, DE
• Hongbo Deng · Southborough, US
• Ralf Biesinger · Ludwigshafen, DE
• Xinyuan Wu · Newton, US
• Harald Bluhm · Dossenheim, DE
• Irving Sucholeiki · Watertown, US
• Arthur G. Taveras · Rockaway, US

Key dates

• Filing date: Dec 7, 2007
• Grant date: Sep 14, 2010
• Expiry date: Dec 7, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds having the following formulas:wherein R1, R2, R3, and R4 are as defined in the specification. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds amide containing heterobicyclic compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.